Exclusion Criteria:~1. Evidence that the primary basis for cognitive impairment is neurodegenerative disease
other than AD, including, but not limited to, vascular dementia, dementia with Lewy bodies, and Parkinson's
disease.~2. Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline,
defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of
suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide.~3. History
of major and active psychiatric disorder, moderate to severe depressive symptoms, and or other concurrent
medical condition that, EIP-VX17-745-304, Version 1.0, 17 November, 2017 Page 7 of 46 EIP Pharma, LLC
Confidential in the opinion of the Investigator, might compromise safety and/or compliance with study
requirements.~4. Diagnosis of alcohol or drug abuse within the previous 2 years.~5. History of cancer within
the last 5 years, except basal cell carcinoma, squamous skin carcinoma, prostate cancer or carcinoma in situ
with no significant progression over the past 2 years.~6. Poorly controlled clinically significant medical
illness.~7. History of serum B12 abnormality, anemia with hemoglobin ≤10 g/dL, thyroid function abnormality,
electrolyte abnormality, or positive syphilis serology that have not been corrected and/or otherwise
addressed.~8. History of epilepsy or unexplained seizure within the past 5 years.~9. Aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) >3 Ã— the upper limit of normal (ULN), total bilirubin >2 Ã— ULN,
and/or International Normalized Ratio (INR) >1.5~10. Known human immunodeficiency virus, hepatitis B, or active
hepatitis C virus infection.~11. Subject participated in a study of an investigational drug less than 3 months
or 5 half-lives of the investigation drug, whichever is longer, before enrollment in this study.
